APA (7th ed.) Citation

Dooley, K. E., Sayre, P., Borland, J., Purdy, E., Chen, S., Song, I., . . . Flexner, C. (2013). Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: Results of a phase 1 study among healthy subjects. Journal of acquired immune deficiency syndromes (1999), 62(1), 21. https://doi.org/10.1097/QAI.0b013e318276cda9

Chicago Style (17th ed.) Citation

Dooley, Kelly E., et al. "Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily with Rifampin or Once Daily with Rifabutin: Results of a Phase 1 Study Among Healthy Subjects." Journal of Acquired Immune Deficiency Syndromes (1999) 62, no. 1 (2013): 21. https://doi.org/10.1097/QAI.0b013e318276cda9.

MLA (9th ed.) Citation

Dooley, Kelly E., et al. "Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily with Rifampin or Once Daily with Rifabutin: Results of a Phase 1 Study Among Healthy Subjects." Journal of Acquired Immune Deficiency Syndromes (1999), vol. 62, no. 1, 2013, p. 21, https://doi.org/10.1097/QAI.0b013e318276cda9.